Synthetic TLR4 Agonists with C3 Dehydroxylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TLR4 agonists, such as MPL and AGPs, have limitations including chemical heterogeneity and complex synthesis processes, which affect their efficacy and usability as vaccine adjuvants and immunostimulants.
Innovation Solution
Development of novel synthetic compounds, specifically those of formula 1, which are more effective TLR4 receptor agonists with simpler and more industrially scalable synthesis processes, eliminating the need for hydroxyl groups on C3 and using non-hydroxylated myristic acid chains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monophosphoryl lipid A (MPL) is used as TLR4 agonist, then immunostimulatory activity is maintained, but chemical heterogeneity and complex synthesis processes occur
Solution Approach 1:
The patent modifies the chemical structure of lipid A by changing specific parameters (removing hydroxyl groups at C3 position, adjusting acyl chain composition) to create a homogeneous synthetic compound that maintains immunostimulatory activity while eliminating chemical heterogeneity and simplifying synthesis processes
Solution Approach 2:
The invention focuses on specific local modifications of the lipid A molecule, particularly at the C3 position where hydroxyl groups are removed and specific acyl chains are introduced, creating a targeted structural change that improves manufacturability while preserving biological activity
2Reliability
If AGPs (Corixa compounds) are used as TLR4 agonists, then potent agonist activity is achieved, but synthesis processes become complex
Solution Approach 1:
The patent extracts and removes the complex synthesis steps from the AGP production process by using a simplified approach that avoids the need for multiple protection and deprotection steps, directly synthesizing the compound without hydroxyl groups at C3 position
Solution Approach 2:
Instead of building up the complex structure step-by-step through conventional synthesis, the invention inverts the approach by starting with a simpler core structure and adding only the necessary components, thereby reducing synthesis complexity while maintaining agonist activity
3Reliability
If natural LPS is used as TLR4 agonist, then strong activation effect is obtained, but excessive toxicity occurs
Solution Approach 1:
The patent converts the harmful toxicity of natural LPS into a benefit by selectively removing the toxic hydroxyl groups at C3 position while retaining the essential activating structure, thereby reducing toxicity while maintaining or improving activation effect
Solution Approach 2:
The invention creates a simplified copy of the lipid A structure that lacks the toxic hydroxyl groups at C3 position, producing a analogue that maintains the essential TLR4 activation function while eliminating the harmful toxic effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new compounds, such as FP11, demonstrate enhanced TLR4 agonist activity with improved tolerability and reduced toxicity, offering potential as effective vaccine adjuvants and immunostimulants with streamlined synthesis.
Implementation Method 1
Lipid A agonistic activity is based on its binding affinity (ability to bind) to the TLR4 co-receptor, Myeloid Differentiation factor 2, MD-2
Implementation Method 2
MPL is a molecule identical to lipid A, but with the C 1 position stripped of the phosphate group through chemical modification
Implementation Method 3
AGPs are comprised of a monosaccharide unit linked by glycosidation to a unit of an aminoalkyl aglycone N-acylate
Implementation Method 4
Also compound SDZ MRL 953 demonstrated a potent activity in stimulating the release of inflammatory cytokines like interleukin-6 (IL-6), interleukin-8 (IL-8) and TNF-α factor
Data Source
Figure 1A~2B
Figure 3
Figure 4A~4H
AI summary
The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. The compounds have general formula (1), wherein R1 is a saturated C8-C16 aliphatic chain having a =0 on C1, said chain being free from -OH substituents on C3, wherein R2 is a saturated C8-C16 aliphatic chain having a =O on C1, said chain being free from -OH substituents on C3, wherein R3 is a saturated C8-C16 aliphatic chain having a =O on C1, said chain being free from -OH substituents on C3; wherein R4 is a hydrogen atom (H) or a phosphate group (PO4 2-).